METiS TechBio will apply its AI-driven AiLNP ionizable lipid platform to discover LNPs designed to deliver therapeutics beyond the liver, under a collaboration with Eli Lilly worth up to $1.1 billion in milestones.
|Articles|September 27, 2006
Mobius from Millipore
Millipore Corporation's (Billerica, MA; www.millipore.com/mobius) new Mobius disposable TFF assemblies offer flexible, self-contained solutions that reduce validation efforts, increase process speed and mitigate risks.
Advertisement
Millipore Corporation's(Billerica, MA;
www.millipore.com/mobius
) new Mobius disposable TFF assemblies,offers flexible, self-contained solutions that reduce validation efforts, increaseprocess speed and mitigate risks. Millipore's Pellicon cassettes are used with the disposable TFF assemblies.
Advertisement
Related to this article
Interim phase 1 data presented at UEG Week 2026 showed Bionyra Pharma’s Fc-engineered anti-TL1A antibody BYN-002 suppressed soluble TL1A with a half-life supporting potential every-3-to-6-month maintenance dosing in IBD.
Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial.
Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin.
The American Association of Pharmaceutical Scientists appointed former president Patrick J. Sinko as chief science officer to lead its scientific strategy, programming, and peer-reviewed journals.
The FDA grants accelerated approval to dostarlimab for rectal cancer, Lilly reports one-year remission data for pediatric ulcerative colitis, and Johnson & Johnson shares longer-term fistula remission results for Tremfya.
Accelerated approval for dostarlimab-gxly (Jemperli) pairs a single-arm phase 2 dataset with an FDA-authorized biomarker test and confirmatory requirements.
BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs.
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
The BioPharm Brief: New Approval, Pediatric Progress, and Durable Remission
4
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
5